Get started
Author

Dzintars Gotham

Observed names: D Gotham, D. Gotham, Gotham, D, Gotham, Dzintars
Observed institutions: University Hospitals Birmingham NHS Foundation Trust, University of Liverpool, King's College London, Chelsea and Westminster Hospital NHS Foundation Trust, Public Health England, National Institute for Health and Care Research, University of Oxford, World Health Organization Regional Office for Europe, Medway NHS Foundation Trust, Medicines Patent Pool, Public Health Scotland, National Records of Scotland, Médecins Sans Frontières, Nepal Health Research Council, Chelsea and Westminster Hospital, Oxford University Clinical Research Unit, King's College Hospital, St Stephen’s AIDS Trust, Intensive Care National Audit & Research Centre, Oxford University Clinical Research Unit Indonesia, Imperial College London
ORCID: 0000-0003-0359-1259
Observed ORCID: 0000-0003-0359-1259
OpenAlex ID: A5019711864
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 493
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 369
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 324
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 290
Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?
2018 · Andrew Hill, Sophie L. Hughes, et al. · Journal of Virus Eradication · 137
PDF
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
2023 · Obbina Abani, Ali Abbas, et al. · The Lancet · 129
Estimated costs of production and potential prices for the WHO Essential Medicines List
2018 · Andrew M Hill, Melissa J Barber, et al. · BMJ Global Health · 101
PDF
Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C
2016 · Andrew Hill, Bryony Simmons, et al. · Journal of Virus Eradication · 82
PDF
Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications
2021 · Brian Godman, Andrew Hill, et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 75
PDF
Reimbursement models to tackle market failures for antimicrobials: Approaches taken in France, Germany, Sweden, the United Kingdom, and the United States
2020 · Dzintars Gotham, Lorenzo Moja, et al. · Health Policy · 70
PDF
Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment
2016 · Andrew Hill, Dzintars Gotham, et al. · BMJ Open · 68
PDF
Quantifying changes in global health inequality: the Gini and Slope Inequality Indices applied to the Global Burden of Disease data, 1990–2017
2019 · Fridolin Steinbeis, Dzintars Gotham, et al. · BMJ Global Health · 65
PDF
Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries
2020 · Melissa J. Barber, Dzintars Gotham, et al. · Journal of Virus Eradication · 60
PDF
Production costs and potential prices for biosimilars of human insulin and insulin analogues
2018 · Dzintars Gotham, Melissa J Barber, et al. · BMJ Global Health · 60
PDF
Estimated Sustainable Cost-Based Prices for Diabetes Medicines
2024 · Melissa J. Barber, Dzintars Gotham, et al. · JAMA Network Open · 59
PDF
Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14 894 patients across 14 trials
2020 · Victoria Pilkington, Sophie L. Hughes, et al. · AIDS · 53
Patent pooling to increase access to essential medicines
2019 · Esteban Burrone, Dzintars Gotham, et al. · Bulletin of the World Health Organization · 46
PDF
Pricing of oral generic cancer medicines in 25 European countries; findings and implications
2019 · Brian Godman, Andrew Hill, et al. · Generics and Biosimilars Initiative Journal · 44
PDF
Estimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis
2017 · Andrew Hill, Christopher Redd, et al. · BMJ Open · 43
PDF
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2023 · O Abani, A Abbas, et al. · The Lancet Diabetes & Endocrinology · 41
PDF
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial
2024 · Saul N Faust, Richard Haynes, et al. · The Lancet Child & Adolescent Health · 39
PDF
Public investments in the development of GeneXpert molecular diagnostic technology
2021 · Dzintars Gotham, Lindsay McKenna, et al. · PLoS ONE · 38
Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries
2015 · Andrew Hill, Dzintars Gotham, et al. · Journal of Virus Eradication · 35
PDF
Candidates for inclusion in a universal antiretroviral regimen
2017 · Dzintars Gotham, Andrew Hill, et al. · Current Opinion in HIV and AIDS · 33
Novel approaches to enable equitable access to monoclonal antibodies in low- and middle-income countries
2024 · Shelly Malhotra, Anne-Isabelle Cameron, et al. · PLOS Global Public Health · 27
Works count: 74
Citation count: 2,981
H-index: 27
I10-index: 34
Year
Topic
Type